John Carroll: "As Trump 2.0 continues its assault on federally-funded research, a new study highlights what's at stake"
The article argues that the Trump administration's policies threaten federally-funded research, highlighting a shift where the biopharma industry now dominates cancer research priorities. It suggests this transition poses significant risks to public health outcomes by reducing federal oversight and influence.